Injection of MMP-13-selective inhibitor Zn2+-chelating compound, which targets the catalytic domain of MMP-13 [139], significantly reduced the level of bone destruction and delayed MM growth in an immunocompetent syngeneic mouse model with multiple myeloma [74]. The gene discussed is MMP13; the disease is Miyoshi myopathy.